July 2024
1. LUNAGARIYA Y, Shah M, Lad S, Chauhan S, et al
   Comparing Short-Term Dual vs Standard Quadruple Therapy for Helicobacter pylori Eradication.
   Am J Gastroenterol. 2024 Jul 17. doi: 10.14309/ajg.0000000000002882.
   

   >> Share

   
   
2. OH JH, Kim HS, Cheung DY, Lee HL, et al
   Randomized, Double-blind, Active-controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan compared to Esomeprazole in Erosive Esophagitis.
   Am J Gastroenterol. 2024 Jul 3. doi: 10.14309/ajg.0000000000002929.
   

   >> Share

   
   June 2024
3. HAN YM, Yoon JH, Yoo S, Chung SJ, et al
   Visceral Adipose Tissue Reduction Measured by Deep Neural Network Architecture Improved Reflux Esophagitis Endoscopic Grade.
   Am J Gastroenterol. 2024;119:1117-1125.
   

   >> Share

   
   April 2024
4. KRAUSE AJ, Greytak M, Kaizer AM, Carlson DA, et al
   Diagnostic Yield of Ambulatory Reflux Monitoring Systems for Evaluation of Chronic Laryngeal Symptoms.
   Am J Gastroenterol. 2024;119:627-634.
   

   >> Share

   
   February 2024
5. DU RC, Lu NH, Hu Y
   Is 10-Day Vonoprazan With High-Dose Amoxicillin Dual Therapy Efficient for Eradicating Helicobacter pylori Infection in China?
   Am J Gastroenterol. 2024 Feb 19. doi: 10.14309/ajg.0000000000002641.
   

   >> Share

   
   
6. ZHUANG Q, Chen S, Zhou X, Jia X, et al
   Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis.
   Am J Gastroenterol. 2024 Feb 12. doi: 10.14309/ajg.0000000000002714.
   

   >> Share

   
   
7. CHEN L, Wang R, Peng T, Ye L, et al
   Mantle Cell Lymphoma Presenting as Erosive Duodenitis.
   Am J Gastroenterol. 2024;119:240.
   

   >> Share

   
   January 2024
8. CHEN F, Liu Y, Xing X, Yang J, et al
   An uncommon chest pain after endoscopic hemostasis of peptic ulcer.
   Am J Gastroenterol. 2024 Jan 15. doi: 10.14309/ajg.0000000000002652.
   

   >> Share

   
   
9. YASUMURA K, Tochio T, Ohana M
   Refractory gastric ulcer in the antrum.
   Am J Gastroenterol. 2024 Jan 15. doi: 10.14309/ajg.0000000000002651.
   

   >> Share

   
   December 2023
10. VIMONSUNTIRUNGSRI T, Thungsuk R, Nopjaroonsri P, Faknak N, et al
    The efficacy of metoclopramide for gastric visualization by endoscopy in patients with active upper gastrointestinal bleeding: double-blind randomized controlled trial.
    Am J Gastroenterol. 2023 Dec 7. doi: 10.14309/ajg.0000000000002620.
    

    >> Share

    
    
11. ZAMANI M, Alizadeh-Tabari S, Chan WW, Talley NJ, et al
    Association Between Anxiety/Depression and Gastroesophageal Reflux: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2023;118:2133-2143.
    

    >> Share

    
    November 2023
12. BUJANDA L, Nyssen OP, Ramos J, Bordin DS, et al
    Effectiveness of Helicobacter pylori treatments according to antibiotic resistance.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002600.
    

    >> Share

    
    
13. YAN TL, Wang JH, He XJ, Zhu YB, et al
    Ten-day vonoprazan-amoxicillin dual therapy versus standard fourteen-day Bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002592.
    

    >> Share

    
    
14. ZULLO A, Gatta L, De Francesco V
    Randomized Controlled Trials for Helicobacter pylori Infection: What We Should Compare.
    Am J Gastroenterol. 2023;118:2094.
    

    >> Share

    
    
15. KOUNTOURAS J
    Thinking of the Long Puzzling Issue of Several Suboptimal Treatments of Helicobacter pylori Infection.
    Am J Gastroenterol. 2023;118:2093.
    

    >> Share

    
    September 2023
16. SHUNG DL, Lin JK, Laine L
    Achieving Value by Risk Stratification with Machine Learning Model or Clinical Risk Score in Acute Upper Gastrointestinal Bleeding: A Cost Minimization Analysis.
    Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002520.
    

    >> Share

    
    August 2023
17. TAPPER EB, Zhao Z, Parikh ND
    An emulated clinical trial of deprescribing proton pump inhibitors in patients with cirrhosis.
    Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002462.
    

    >> Share

    
    June 2023
18. GREENAN G, Rogers BD, Gyawali CP
    PROXIMAL GASTRIC PRESSURIZATION FOLLOWING SLEEVE GASTRECTOMY ASSOCIATES WITH GASTROESOPHAGEAL REFLUX.
    Am J Gastroenterol. 2023 Jun 19. doi: 10.14309/ajg.0000000000002374.
    

    >> Share

    
    
19. CORAZZIARI ES, Gasbarrini A, D'Alba L, D'Ovidio V, et al
    Poliprotect vs Omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions: A Randomized, Controlled Trial.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002360.
    

    >> Share

    
    May 2023
20. GRAHAM DY
    It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials.
    Am J Gastroenterol. 2023 May 15. doi: 10.14309/ajg.0000000000002298.
    

    >> Share

    
    
21. CHITTAJALLU V, Vozzo C, Friedman K, Glessing B, et al
    Odynophagia Secondary to Mpox-Associated Esophageal Ulceration.
    Am J Gastroenterol. 2023;118:774.
    

    >> Share

    
    March 2023
22. HSU PI, Chen KY, Tai WC, Yang JC, et al
    Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial.
    Am J Gastroenterol. 2023 Mar 20. doi: 10.14309/ajg.0000000000002255.
    

    >> Share

    
    
23. DENG C, Wu S, Xu F, Zhou Z, et al
    Underwater anti-reflux mucosectomy for refractory gastroesophageal reflux disease:A rapid and simple technique for endoscopic treatment.
    Am J Gastroenterol. 2023 Mar 20. doi: 10.14309/ajg.0000000000002256.
    

    >> Share

    
    January 2023
24. YUNUSA I, Love BL
    Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
    Am J Gastroenterol. 2023 Jan 25. doi: 10.14309/ajg.0000000000002146.
    

    >> Share

    
    
25. CUMMINGS LC, Hojat LS, Nguyen DC, Stempak LM, et al
    Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success.
    Am J Gastroenterol. 2023 Jan 6. doi: 10.14309/ajg.0000000000002085.
    

    >> Share

    
    December 2022
26. VISAGGI P, Del Corso G, Gyawali CP, Ghisa M, et al
    Ambulatory pH-Impedance Findings Confirm that Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2022 Dec 29. doi: 10.14309/ajg.0000000000002173.
    

    >> Share

    
    
27. ROSEN R
    Gastroesophageal reflux treatment in infancy through young adulthood.
    Am J Gastroenterol. 2022 Dec 24. doi: 10.14309/ajg.0000000000002160.
    

    >> Share

    
    
28. QIAN HS, Li WJ, Dang YN, Li LR, et al
    Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Am J Gastroenterol. 2022 Dec 2. doi: 10.14309/ajg.0000000000002086.
    

    >> Share

    
    November 2022
29. RUBENSTEIN JH
    Gastroesophageal Reflux Disease Is Not a Great Screening Criterion: Time to Move on to Other Strategies for Controlling the Burden of Esophageal Adenocarcinoma.
    Am J Gastroenterol. 2022;117:1759-1761.
    

    >> Share

    
    October 2022
30. KAMAL AN, Wang CJ, Triadafilopoulos G, Clarke JO, et al
    Healthcare Disparities in Gastroesophageal Reflux Disease for Hispanic and Latino Americans: A Solution-Oriented Approach for Improvement.
    Am J Gastroenterol. 2022 Oct 7. pii: 00000434-990000000-00479.
    

    >> Share

    
    
31. GU C, Olszewski T, King KL, Vaezi MF, et al
    The Effects of Modifying Amount and Type of Dietary Carbohydrate on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial.
    Am J Gastroenterol. 2022;117:1655-1667.
    

    >> Share

    
    September 2022
32. MEGRAUD F, Graham DY, Howden CW, Trevino E, et al
    Rates of Antimicrobial Resistance in Helicobacter pylori Isolates from Clinical Trial Patients Across the US and Europe.
    Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00527.
    

    >> Share

    
    
33. ELHENCE A, Ghoshal UC
    Sleep Position and Reflux: Do Not Lose Sleep Over It.
    Am J Gastroenterol. 2022;117:1539.
    

    >> Share

    
    August 2022
34. HASEEB M, McCarty TR, Jirapinyo P, Thompson CC, et al
    Letter to the Editor in Response to ACG Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2022 Aug 23. pii: 00000434-990000000-00481.
    

    >> Share

    
    July 2022
35. ZHOU Y
    Proton Pump Inhibitors and Risk of Mortality: Longer and More Dangerous?
    Am J Gastroenterol. 2022;117:1171-1172.
    

    >> Share

    
    June 2022
36. YADLAPATI R, Gyawali CP, Masihi M, Carlson DA, et al
    OPTIMAL WIRELESS REFLUX MONITORING METRICS TO PREDICT DISCONTINUATION OF PROTON PUMP INHIBITOR THERAPY: Optimal Reflux Monitoring Metrics to Predict PPI Discontinuation.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00403.
    

    >> Share

    
    
37. AZHARI H, King JA, Coward S, Windsor JW, et al
    The Global Incidence of Peptic Ulcer Disease is Decreasing since the Turn of the 21st Century: A Study of the Organisation for Economic Co-operation and Development (OECD): Global Incidence of Peptic Ulcer Disease.
    Am J Gastroenterol. 2022 Jun 2. pii: 00000434-990000000-00385.
    

    >> Share

    
    
38. WANG R, Bai D, Xiang W, Chen XZ, et al
    Tibetan Ethnicity, Birthplace, Helicobacter pylori Infection, and Gastric Cancer Risk.
    Am J Gastroenterol. 2022;117:1010.
    

    >> Share

    
    May 2022
39. HO JJC, Navarro M, Sawyer K, Elfanagely Y, et al
    Helicobacter pylori Antibiotic Resistance in the United States Between 2011-2021: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2022 May 5. pii: 00000434-990000000-00369.
    

    >> Share

    
    
40. PARK JY, Yoo J, Jeon J, Kim J, et al
    Proton pump inhibitors and risk of cardiovascular disease: a self-controlled case series study.
    Am J Gastroenterol. 2022 May 4. pii: 00000434-990000000-00361.
    

    >> Share

    
    April 2022
41. DEWITT J, Kessler W, Wo J, Stainko S, et al
    SYMPTOM ASSOCIATION FOR GASTROESOPHAGEAL REFLUX DISEASE BY PH MONITORING AFTER PERORAL ENDOSCOPIC MYOTOMY: GERD and symptoms after POEM.
    Am J Gastroenterol. 2022 Apr 25. pii: 00000434-990000000-00351.
    

    >> Share

    
    March 2022
42. VENKAT PG, Longstreth GF
    Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome.
    Am J Gastroenterol. 2022 Mar 28. pii: 00000434-990000000-00307.
    

    >> Share

    
    
43. LAINE L, Sharma P, Mulford DJ, Hunt B, et al
    PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS.
    Am J Gastroenterol. 2022 Mar 16. pii: 00000434-990000000-00284.
    

    >> Share

    
    January 2022
44. GRAHAM DY, Moss SF
    Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: When, How, Why.
    Am J Gastroenterol. 2022 Jan 25. pii: 00000434-990000000-00227.
    

    >> Share

    
    December 2021
45. SCHUITENMAKER JM, van Dijk M, Oude Nijhuis RAB, Smout AJPM, et al
    Associations Between Sleep Position and Nocturnal Gastroesophageal Reflux: A Study Using Concurrent Monitoring of Sleep Position and Esophageal pH and Impedance.
    Am J Gastroenterol. 2021 Dec 20. pii: 00000434-990000000-00170.
    

    >> Share

    
    
46. VITOR MS, Tiago LC, Marta F, Tiago CG, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    

    >> Share

    
    
47. MACEDO SILVA V, Lima Capela T, Freitas M, Curdia Goncalves T, et al
    P020 Proton Pump Inhibitor Therapy: Providing "Acid" Outcomes in Patients With Inflammatory Bowel Disease Under Infliximab Treatment.
    Am J Gastroenterol. 2021;116.
    

    >> Share

    
    November 2021
48. KATZ PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, et al
    ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2021 Nov 22. pii: 00000434-990000000-00154.
    

    >> Share

    
    September 2021
49. BHATTACHARYA S, Blau JE, Cochran C, Auh S, et al
    Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome.
    Am J Gastroenterol. 2021 Sep 13. pii: 00000434-990000000-00098.
    

    >> Share

    
    August 2021
50. CHENG YY, Tsai MC, Wei JC
    Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy".
    Am J Gastroenterol. 2021 Aug 27. pii: 00000434-990000000-00086.
    

    >> Share

    
    
51. LV XH, Wang ZJ, Yang JL
    Proton Pump Inhibitors and COVID-19: Confusing Status Quo.
    Am J Gastroenterol. 2021 Aug 16. pii: 00000434-990000000-00070.
    

    >> Share

    
    July 2021
52. HE Q, Xia B, Meng W, Fan D, et al
    No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants.
    Am J Gastroenterol. 2021 Jul 27. pii: 00000434-990000000-00057.
    

    >> Share

    
    
53. SINGH AD, Zhang X, Anwer F, Bhatt A, et al
    Isolated Gastric Amyloid Light Chain Amyloidosis Causing Upper Gastrointestinal Bleeding.
    Am J Gastroenterol. 2021 Jul 23. pii: 00000434-990000000-00056.
    

    >> Share

    
    
54. RIBOLSI M, Luca Guarino MP, Balestrieri P, Altomare A, et al
    The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough.
    Am J Gastroenterol. 2021 Jul 21. pii: 00000434-990000000-00054.
    

    >> Share

    
    
55. LABENZ C, Labenz J
    Proton Pump Inhibitors in Patients With Liver Cirrhosis: Evidence to Improve Their Battered Reputation.
    Am J Gastroenterol. 2021 Jul 19. pii: 00000434-990000000-00048.
    

    >> Share

    
    
56. ZHANG B, Hu Y, Shi X, Li W, et al
    Integrative Effects and Vagal Mechanisms of Transcutaneous Electrical Acustimulation on Gastroesophageal Motility in Patients With Gastroesophageal Reflux Disease.
    Am J Gastroenterol. 2021;116:1495-1505.
    

    >> Share

    
    June 2021
57. SHIN GY, Park JM, Hong J, Cho YK, et al
    Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Am J Gastroenterol. 2021;116:1211-1219.
    

    >> Share

    
    May 2021
58. LIU JJ, Sloan ME, Owings AH, Figgins E, et al
    Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
    Am J Gastroenterol. 2021 May 27. pii: 00000434-900000000-98767.
    

    >> Share

    
    
59. WATANABE K, Shimodaira Y, Takahashi S, Fukuda S, et al
    Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
    Am J Gastroenterol. 2021 May 13. pii: 00000434-900000000-98781.
    

    >> Share

    
    
60. BOTTERI E, Gallus S, Lugo A
    Response to Hoffmeister et al.
    Am J Gastroenterol. 2021;116:1093-1094.
    

    >> Share

    
    
61. TSAY CJ, Protiva P
    Chronic Mesenteric Ischemia With Peristaltic Blanching.
    Am J Gastroenterol. 2021;116:870.
    

    >> Share

    
    April 2021
62. NYSSEN OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, et al
    Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
    Am J Gastroenterol. 2021 Apr 8. pii: 00000434-900000000-98822.
    

    >> Share

    
    February 2021
63. BISSELING TM, van Laarhoven A, Huijbers A, Brink M, et al
    Coronavirus Disease-19 Presenting as Esophageal Ulceration.
    Am J Gastroenterol. 2021;116:421-424.
    

    >> Share

    
    January 2021
64. SUGIYAMA T
    Long-Term Safety of Proton Pump Inhibitors: Bone Fracture Risk as an Example.
    Am J Gastroenterol. 2021 Jan 22. pii: 00000434-900000000-98932.
    

    >> Share

    
    December 2020
65. LISA Y, Robert C
    P051 Proton Pump Inhibitors are Associated with Less Severe Periodontal Disease: Considerations for IBD Patients.
    Am J Gastroenterol. 2020;115.
    

    >> Share

    
    November 2020
66. ALMARIO CV, Chey WD, Spiegel BMR
    Response to Hajifathalian and Katz Regarding Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1922-1923.
    

    >> Share

    
    
67. BOUSHEY H, Gonda I
    Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1921.
    

    >> Share

    
    
68. TARLOW B, Gubatan J, Khan MA, Cholankeril G, et al
    Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?
    Am J Gastroenterol. 2020;115:1920-1921.
    

    >> Share

    
    
69. HADI YB, Naqvi SF, Kupec JT
    Risk of COVID-19 in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020;115:1919-1920.
    

    >> Share

    
    
70. HAJIFATHALIAN K, Katz PO
    Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors".
    Am J Gastroenterol. 2020;115:1918-1919.
    

    >> Share

    
    
71. ABY ES, Rodin H, Debes JD
    Proton Pump Inhibitors and Mortality in Individuals With COVID-19.
    Am J Gastroenterol. 2020;115:1918.
    

    >> Share

    
    
72. KOTHARI TH, Enslin S, Cheong J, Kaul V, et al
    Treatment of Bouveret Syndrome Using an Ultrathin Gastroscope: Making the Best out of a Tight Situation!
    Am J Gastroenterol. 2020;115:1748.
    

    >> Share

    
    October 2020
73. GUO H, Lam AY, Shaheen AA, Forbes N, et al
    Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States.
    Am J Gastroenterol. 2020 Oct 22. doi: 10.14309/ajg.0000000000000997.
    

    >> Share

    
    
74. BOUSHEY H, Gonda I
    Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 19. doi: 10.14309/ajg.0000000000001014.
    

    >> Share

    
    
75. HAJIFATHALIAN K, Katz PO
    Regarding "Increased Risk of COVID-19" in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000920.
    

    >> Share

    
    
76. HADI YB, Naqvi SF, Kupec JT
    Risk of COVID-19 in Patients Taking Proton Pump Inhibitors.
    Am J Gastroenterol. 2020 Oct 1. doi: 10.14309/ajg.0000000000000949.
    

    >> Share

    
    
77. MARTIN TA, Wan DW, Hajifathalian K, Tewani S, et al
    Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A Matched Case-Control Study.
    Am J Gastroenterol. 2020;115:1609-1616.
    

    >> Share

    
    September 2020
78. ABY ES, Rodin H, Debes JD
    Proton Pump Inhibitors and Mortality in Individuals With COVID-19.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000992.
    

    >> Share

    
    
79. HALLAND M, Bharucha AE, Crowell MD, Ravi K, et al
    Effects of Diaphragmatic Breathing on the Pathophysiology and Treatment of Upright Gastroesophageal Reflux: A Randomized Controlled Trial.
    Am J Gastroenterol. 2020 Sep 30. doi: 10.14309/ajg.0000000000000913.
    

    >> Share

    
    May 2020
80. LONGSTRETH GF
    Internists' Misconceptions About PPIs: Increasing Knowledge and Implementing Guidelines.
    Am J Gastroenterol. 2020;115:681-682.
    

    >> Share

    
    
81. BAZERBACHI F, Chandrasekhara V
    Ulcere Perfore-Bouche.
    Am J Gastroenterol. 2020;115:649.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share